Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback